Cargando…
Time to market for drugs approved in Canada between 2014 and 2018: an observational study
OBJECTIVES: This study examines the length of time between when a patent application is filed in Canada for a new drug and when it is available for patients (time to market) and various components of that time. It also looks at whether various factors explain the time between patent application to N...
Autor principal: | Lexchin, Joel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258566/ https://www.ncbi.nlm.nih.gov/pubmed/34226224 http://dx.doi.org/10.1136/bmjopen-2020-047557 |
Ejemplares similares
-
Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study
por: Lexchin, Joel
Publicado: (2018) -
Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis
por: Lexchin, Joel
Publicado: (2017) -
Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
por: Lexchin, Joel
Publicado: (2014) -
How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009
por: Lexchin, Joel
Publicado: (2014) -
Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
por: Diep, Dion, et al.
Publicado: (2020)